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Abstract
Heart failure (HF) and atrial fibrillation (AF) frequently 
coexist and have emerged as major cardiovascular 
epidemics. There is growing evidence that AF is an in-
dependent prognostic marker in HF and affects patients 
with both reduced as well as preserved LV systolic func-
tion. There has been a general move in clinical practice 
from a rhythm control to a rate control strategy in HF 
patients with AF, although recent data suggests that 
rhythm control strategies may provide better outcomes 
in selected subgroups of HF patients. Furthermore, 
various therapeutic modalities including pace and ab-
late strategies with cardiac resynchronisation or radio-
frequency ablation have become increasingly adopted, 
although their role in the management of AF in patients 
with HF remains uncertain. This article presents an 
overview of the multidimensional impact of AF in pa-
tients with HF. Relevant literature is highlighted and the 
effect of various therapeutic modalities on prognosis is 
discussed. Finally, while novel anticoagulants usher in a 
new era in thromboprophylaxis, research continues in a 
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variety of new pathways including selective atrial anti-
arrhythmic agents and genomic polymorphisms in AF 
with HF.
© 2013 Baishideng. All rights reserved.
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Core tip: Atrial fibrillation commonly coexists with heart 
failure and there is growing evidence that it confers an 
adverse prognostic impact on the natural course of the 
disease. This review analyses the demographics and 
relevant literature highlighting this impact as well as 
the effect of various therapeutic modalities in improv-
ing outcomes. Finally some of the future trends in this 
exciting cardiovascular discipline are discussed.
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INTRODUCTION 
Heart failure (HF) and atrial fibrillation (AF) have 
emerged as major global epidemics[1]. Both frequently 
coexist and are associated with several common predis-
posing risk factors such as hypertension, coronary artery 
disease, structural heart disease (non-ischaemic, valvular), 
diabetes mellitus, obesity and obstructive sleep apnoea. 
This co-prevalence increases with advancing age and each 
predicts/compounds the course of  the other[2,3].
Data from Acute Decompensated Heart Failure Na-
tional Registry demonstrated a 30% prevalence of  AF 
among patients admitted with acute decompensated HF[4]. 
The EuroHeart survey looked at HF hospitalisation data 
from 24 countries over a 6-wk duration. It revealed that 
out of  a total of  10701 patients, 34% were known to have 
AF previously while 9% developed new onset AF[5]. There 
is good data suggesting that AF is more prevalent in HF 
with preserved ejection fraction as compared to HF with 
reduced ejection fraction[6-8]. The prevalence of  AF also 
correlates directly with the severity of  HF symptoms. It can 
vary from under 10% in those with functional New York 
Heart Association (NYHA) class 1 to as high as 50% in 
those in NYHA class 4[9]. Similar prevalence figures have 
been reported from the T-wave Alternans in Patients with 
Heart Failure[10] as well. 
PATHOPHYSIOLOGICAL INTER-
RELATIONSHIP
The interplay between HF and AF is complex. HF pre-
dicts the development of  AF and conversely AF pre-
disposes to HF[2]. There are a number of  mechanisms 
through which HF predisposes to an arrhythmogenic 
atrial substrate. These include elevated left sided-filling 
pressures, mitral regurgitation, atrial enlargement, intersti-
tial fibrosis and electromechanical remodelling[3]. Activa-
tion of  autonomic and renin-angiotensin axis contributes 
while changes in the intracellular calcium are thought to 
play a role as well[11].
Conversely, AF can lead to HF through multiple ad-
verse effects including loss of  atrial systole, functional 
mitral/tricuspid regurgitation, tachycardiomyopathy and 
reduced ventricular diastolic filling time[2]. Irregularity 
in the RR interval can also have a potentially deteriorat-
ing influence on cardiac output irrespective of  the heart 
rate[12]. Moreover, deterioration of  sinus rhythm into AF 
in patients with HF can lead to acute decompensation. A 
prospective study of  344 HF patients (who were in sinus 
rhythm at baseline) revealed significant haemodynamic 
deterioration with the onset of  AF. Development of  AF 
in this cohort led to reduced cardiac output, bi-atrial dila-
tation and functional atrioventricular valve regurgitation. 
This was reflected as a decline in the functional NYHA 
symptom class as well as peak exercise oxygen consump-
tion[13]. Details of  the pathophysiological pathways in-
volved are beyond the remit of  this review and have been 
reviewed well previously[14].
EPIDEMIOLOGY
According to the National Health And Nutrition Examina-
tion Survey, the prevalence of  HF in Americans older than 
20 years of  age, is around 5.7 million (2.4%). It ranges from 
around 1.5% in those over 40 years to as high as 11% in the 
above 80 years age group. The lifetime likelihood of  devel-
oping HF at the age of  forty years has been estimated as 1 
in 5[15]. Similarly, estimate from existing data suggests that as 
many as 30 million people in Europe are living with HF[16]. 
HF incidence also increases progressively with age ranging 
from a rate of  1.4 per 1000 person-years in 55-59 year-old 
group to 47.4 per 1000 person-years in above 90-year-old 
bracket[17]. 
AF is the commonest arrhythmia encountered in 
medical practice[18]. The prevalence of  AF in the United 
States is estimated between 2.7 and 6.1 million. This is 
projected to increase to between 5.6 and 12.0 million[15] 
rising progressively to two and a half-fold by 2050[19]. 
According to the Rotterdam as well as the Framingham 
studies, the lifetime risk of  developing AF has been es-
timated to be around 1 in 4[20,21]. Incidence of  AF also 
increases progressively with age approaching a risk of  
11%-18% by 90 years[22].
IMPACT OF AF ON HF PROGNOSIS 
There has been increasing evidence regarding the adverse 
role of  AF in patients with HF, both in terms of  morbid-
ity as well as prognosis (Table 1). 
Mountantonakis et al[23] analysed the data from patients 
enrolled in the Get With The Guidelines-Heart Failure 
Registry between 2005 and 2010. They looked at 99810 
patients hospitalised with HF across 255 ultrasonography 
sites. One-third of  the cohort had AF and when com-
pared to those in sinus rhythm, it was independently as-
sociated with a longer length of  hospital stay (mean 5 vs 4 
d; P < 0.001) as well as higher in-hospital mortality (4.0% 
vs 2.6%, P < 0.001). A post hoc analysis of  the data from 
the Efficacy of  Vasopressin antagonism in hEart failuRE: 
outcome Study with Tolvaptan looked at the clinical char-
acteristics of  4133 patients out of  which 29% had atrial 
fibrillation/atrial flutter at baseline. In contrast to patients 
in sinus rhythm, AF was found to confer an increased 
risk of  death (HR = 1.23, 95%CI: 1.04-1.46) and cardio-
vascular mortality/HF admission (HR = 1.26, 95%CI: 
1.07-1.47)[24]. Retrospective subset analysis of  studies of  
left ventricular dysfunction (SOLVD) looked at 6517 
patients with LVEF less than 35%[25]. It showed that pa-
tients in AF had an increased risk of  all-cause mortality 
of  34% as compared to 23% for those in sinus rhythm. 
The higher mortality was largely attributable to increased 
risk of  pump failure deaths. These findings were appli-
cable to symptomatic as well as asymptomatic patients. 
Data from the candesartan in heart failure assessment of  
reduction in mortality and morbidity trials demonstrated 
an independent detrimental effect of  AF on long term 
cardiovascular outcomes in HF patients (either reduced 
or preserved LV systolic function)[26]. Similarly, an ad-
justed meta-analysis by Mamas et al[27] has demonstrated a 
worse prognostic impact of  AF in HF. This was based on 
16 studies including 7 randomised trials and 9 observa-
tional studies and included data from 53969 patients. The 
impact of  AF on mortality was reflected by an OR of  1.40 
(95%CI: 1.32-1.48, P < 0.0001) in randomised trials and 
an OR of  1.14 (95%CI: 1.03-1.26, P < 0.05) in observa-
tional trials. This was irrespective of  the LV systolic func-
tion. Middlekauff  et al conducted a prospective study of  
390 patients with NYHA class 3-4 symptoms and a mean 
LV Ejection Fraction (LVEF) of  around 20%. Nineteen 
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percent of  this cohort had AF and this was shown to 
be an independent predictor of  all-cause mortality (ac-
tuarial survival at 1 year with AF 52% vs 71% with sinus 
rhythm). A retrospective study of  944 Medicare benefi-
ciaries looked at 30-d re-hospitalisation and 4-year mor-
tality figures in HF patients older than 65 years (mean age 
of  79 years). No distinction was made between reduced 
and preserved LV systolic function. Risk of  readmission 
was not significantly higher[28] but patients in AF had a 
52% increased likelihood of  mortality over 4 years as 
compared to the ones in sinus rhythm. Finally, Caldwell 
et al[29] studied a cohort of  162 patients who had received 
biventricular device implants for advanced HF (NYHA 3 
and 4). Almost a third of  the patients (who were thought 
to be in sinus rhythm) were found to have silent episodes 
of  paroxysmal AF. There was a trend of  increased mor-
tality but not towards thromboembolic episodes or hos-
pitalisation.
Studies have also focused specifically on the prog-
nostic effect of  AF in ischaemic cardiomyopathy. The 
VALsartan In Acute myocardial iNfarction Trial involved 
over 14000 patients who had suffered from acute myo-
cardial infarction complicated with LV systolic dysfunc-
tion. Patients in AF (both chronic AF at baseline as well 
as new-onset) had higher mortality at 3 years follow up 
as compared to those in sinus rhythm (37% vs 20%)[30]. 
Analysis of  the danish investigations of  arrhythmia and 
mortality on dofetilide in congestive heart failure (DIA-
MOND-CHF) data compared ischaemic vs non ischaemic 
subsets[31]. Three thousand five hundred and eighty-seven 
HF patients were followed for up to 8 years. AF had a 
significant prognostic effect in those with ischaemic heart 
disease (HR = 1.25, 95%CI: 1.09-1.42, P < 0.001] as 
compared to those without ischaemic heart disease (HR 
= 1.01, 95%CI: 0.88-1.16, P = 0.88]. A likely explanation 
may be that AF aggravates ischaemia in such cases (due to 
its association with increased coronary vascular resistance 
and reduced myocardial perfusion) thus affecting progno-
sis adversely[32]. Four-year follow up of  2881 participants 
of  the EChocardiographic Heart Of  England Screening 
study showed similar results[33].
A limited number of  small studies have been con-
ducted to evaluate the temporal significance of  AF and 
it is not entirely clear whether AF prior to HF portends 
a worse prognostic influence or vice versa. The Euro-
Heart Failure survey indicated that new onset acute AF 
is associated with increased mortality as compared to 
chronic AF (12% vs 7%). The likely explanation may be 
related to tachycardia-related adverse haemodynamics as 
well as higher utilization of  anti-arrhythmic agents in the 
acute setting[5]. Data from the community-based study 
by Chamberlain et al[34] divided 1664 HF patients into 3 
groups namely HF without AF (n = 727), HF with AF 
preceding HF (n = 553) and HF with onset of  AF after 
developing HF (n = 384) . In comparison to the group 
in sinus rhythm, the prior-AF group had 29% higher all-
cause mortality. This contrasted to the AF-after-HF group 
who had more than twice the mortality. Similarly, in the 
cohort assessed by Smit et al[35], prognosis of  patients who 
developed AF first was comparatively better as compared 
to those who developed AF after HF. A hundred and 
eighty two consecutive AF patients admitted for HF were 
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Table 1  Prognostic impact of atrial fibrillation in heart failure
Ref.           Setting     n          LVEF Mean follow up AF      Deaths n  (%)  P -value
(yr)    SR   AF
Randomised trials
   Dries et al[25] SOLVD   6517 < 35% 2.8   6% 1395 (23) 149 (34) < 0.0001
   Olsson et al[26] CHARM   7601 All LVEF included 3.1 15% 1466 (23) 365 (32) < 0.001
   Swedberg et al[38] COMET   3029 < 35% 4.8 20%   874 (36) 258 (43) < 0.0005
   Carson et al[109] V-HEFT I&II   1427 < 45% 2.5 19%   480 (39)   75 (36)    NS
   Mathew et al[110] DIG   7788 All LVEF included 3.1 11% 2231 (32) 375 (43) < 0.0001
   Crijns et al[111] PRIME II     409 < 35% 3.4 21%   153 (47)   50 (60) < 0.05
   Pederson et al[112] DIAMOND   3587 < 35% N/A 24% 1951 (73) 634 (77) < 0.001
Observational studies
   Rivero-Ayerza et al[5] EuroHeart Failure Survey 10701 All LVEF included N/A 43%   419 (7) 372 (8) < 0.05
   Ahmed et al[28] Medicare AL     944 All LVEF included 4.0 yr 27%   439 (62) 166 (71) < 0.01
   Mahoney et al[37] Heart Transplantation     234 < 45% 1.1 yr 27%     26 (15)   14 (22)    NS
   Middlekauff et al[113] Heart Transplantation     390 < 35% 265 d 19%   123 (29)   36 (48) < 0.005
   Stevenson et al[114] Heart Transplantation     750 < 40% 2.0 yr 22%   336 (45) 104 (61) < 0.01
   Wojtkowska et al[115] Bilaystok, Poland     120 < 30% 3.0 yr 50%     26 (43)   33 (55)    NS
   Corell et al[116] Danish HF clinic Network   1019 < 45% 1.9 yr 26%   180 (24)   89 (33) < 0.05
   Pai et al[117] Loma Linda VA   8931 All LVEF included 2.5 yr 18% 2164 (28) 529 (44) < 0.0001
   Rusinaru et al[118] Somme, France     368 > 50% N/A 36%   125 (53)   84 (64) < 0.05
   Hamaguchi et al[119] Japanese Registry data   2659 All LVEF included 2.4 yr 35%     N/A     N/A    NS
   Shotan et al[120] National HF Survey, Israel   4102 All LVEF included 4 33% 1480 (54.3) 882 (64.9)     0.000
SR: Sinus rhythm; AF: Atrial fibrillation; LVEF: Left ventricular ejection fraction; NS: Not significant; N/A: Not applicable; SOLVD: Studies of left ventricu-
lar dysfunction; CHARM: Candesartan in heart failure assessment of reduction in mortality and morbidity; COMET: Carvedilol or metoprolol European 
trial; DIG: Digitalis investigation group; DIAMOND: Danish investigations of arrhythmia and mortality on dofetilide.
followed up for 16 ± 11 mo looking at the primary com-
posite end point of  cardiovascular hospitalisation and all-
cause mortality. Seventy five percent of  the cohort were 
known to have AF prior to onset of  HF while 25% devel-
oped AF proceeding HF. When compared to the HF-first 
group, AF-first cohort was less likely to reach the primary 
end-point (49.6% vs 77.7%, P = 0.001). The recently pub-
lished Worcester HF Study has also demonstrated higher 
inpatient death rates as well as post-discharge mortality in 
HF patients with concurrent AF[36].
Other studies, however, have not corroborated this 
independent impact of  AF in HF. For instance, Ma-
honey et al[37] showed that in patients referred for cardiac 
transplantation, AF was not associated with an increased 
mortality. However, given the end-stage disease (where 
prognosis is poor irrespective of  AF) and small numbers 
involved (as well as the cross-sectional design of  the 
study), it is difficult to generalize these results to a wider 
non-selected HF population. Similarly, an analysis of  the 
carvedilol or metoprolol European trial data looked at the 
potential prognostic effect of  AF in HF. When corrected 
for other prognostic markers, AF lost its independent ef-
fect on mortality[38]. However, the criterion for diagnosing 
AF was limited to a single baseline ECG. This may have 
failed to pick up paroxysmal AF or future AF events. 
Thus, the reported prevalence of  19.8% of  the study co-
hort who had AF may represent an underestimate. 
Conversely, HF also impacts prognosis in AF. This is in 
keeping with the bidirectional interaction between the two 
disorders. For instance, the Framingham studies as well as 
EuroHeart Survey have demonstrated the vicious effect 
one condition has on the prognosis of  the other[39,40].
EFFECT OF AF THERAPY ON PROGNOSIS 
Although several of  the studies outlined above demon-
strate an adverse prognostic influence of  AF in HF, yet 
the optimal approach of  managing such patients still re-
mains unclear. 
Pharmacological therapy
Rate control: Ventricular rate control remains a major 
therapeutic target for AF in HF patients. Beta-blockers 
and digoxin (as adjunctive therapy) are the main agents 
available for systolic HF. In addition, non-dihydropyri-
dine calcium channel antagonists (verapamil, diltiazem) 
can be used instead of  beta-blockers in HF with pre-
served EF. Finally, amiodarone can be considered for rate 
control if  combination of  beta-blocker and digoxin is 
inadequate[41]. A number of  studies have demonstrated 
prognostic benefit of  beta-blockers in AF with HF. A 
retrospective analysis of  the US Carvedilol HF trial data 
focused categorically on patients who had AF at the 
time of  enrolment. In comparison to the placebo arm, 
the beta-blocker group had improved LV ejection frac-
tions and better physician-determined global assessment. 
Moreover, there was a tendency towards reduced com-
bined cardiovascular mortality and hospitalisation[42]. The 
digitalis investigation group trial showed that although di-
goxin did not affect mortality in HF, it reduced the num-
ber of  hospital admissions. AF was among the exclusion 
criteria and as such these results may not be applicable to 
AF in HF[43]. Moreover, digoxin loses its effect during pe-
riods of  catecholamine excess and is not recommended 
as monotherapy. Of  note, a recent post-hoc analysis of  
the the Atrial Fibrillation Follow-up Investigation of  
Rhythm Management (AFFIRM) trial has cast doubt on 
the safety of  digoxin in HF patients[44]. It was shown that 
digoxin is associated with increased all-cause mortality 
including a 41% increased risk of  death in patients with 
CHF or LVEF of  less than 40%. This should, however, 
be interpreted with caution as AFFIRM was designed to 
compare rate and rhythm control and patients were not 
randomised to digoxin therapy. Moreover, only 25% of  
the AFFIRM cohort had HF. Moreover, a propensity 
matched analysis of  the same cohort failed to demon-
strate any increase in mortality with digoxin. It is likely 
that the patients on digoxin in the study had higher risk 
of  mortality[45]. Finally, data on the use of  verapamil and 
diltiazem in HF is limited[46]. Verapamil has been shown 
to be useful in HF patients with normal LV systolic func-
tion[47] and current ESC guidelines recommend their use 
in HF with preserved ejection fraction as an alternative to 
beta-blockers[41]. However, these should be avoided in HF 
with reduced ejection fraction due to negative inotropic 
effect on LV contractility[41,48].
Another point that needs further clarification relates 
to the optimal target ventricular rate for permanent AF 
patients in HF. Rate control efficacy in permanent Atrial 
fibrillation: a Comparison between lenient vs strict ratE 
control Ⅱ (RACE Ⅱ) trial looked at lenient (110 bpm) 
vs strict (< 80 bpm) ventricular rate control in patients 
with AF. The primary end-point was a composite of  car-
diovascular death, HF admission, bleeding and embolic 
events including stroke. No significant difference was 
observed in the two arms[49]. Again less than 35% of  the 
cohort had HF (15% in NYHA class 4) and results may 
not be generalizable to the HF patients. Routine versus 
Aggressive upstream rhythm Control for prevention of  
Early atrial fibrillation in HF (RACE Ⅲ) is currently re-
cruiting and will provide definitive answers for the HF 
population[50].
Rhythm control: Amiodarone and dofetilide are the 
main anti-arrhythmic agents assessed in HF patients with 
AF. Survival trial of  antiarrhythmic therapy in conges-
tive heart failure (CHF-STAT) and atrial fibrillation and 
congestive heart failure (AF-CHF) trials have demon-
strated the efficacy of  amiodarone in cardioversion and 
maintenance of  sinus rhythm in patients with moderate 
to severe LV systolic dysfunction[51,52]. Its overall effect 
on mortality was shown to be neutral but long-term clini-
cal use remains limited due to a risk of  significant side 
effects. DIAMOND-CHF trial looked at the effect of  
dofetilide on a cohort of  mainly ischaemic HF patients. 
A pooled sub-study analysis incorporated 506 patients 
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who were in AF. Dofetilide was shown to be safe with 
an overall neutral effect on mortality. It was superior to 
placebo in cardioversion and patients on the drug were 
more likely to be in sinus rhythm at one year as compared 
to placebo (79% vs 42%). Moreover, it was also associ-
ated with reduced HF admissions[53]. Importantly, pa-
tients who converted to sinus rhythm had lower all-cause 
mortality (in the dofetelide as well as placebo arms) sig-
nifying the beneficial prognostic impact of  sinus rhythm. 
However, torsade de pointes (1.6%) remains a cause for 
concern with dofetilide and requires initiation in hospital 
under close monitoring. Furthermore, it is not available 
in Europe. Subsequently, dronedarone (an iodine-free 
amiodarone derivative) was introduced with a promising 
adverse effect profile. A post hoc analysis of  the ATHE-
NA (A Trial with dronedarone to prevent Hospitaliza-
tion or death in patiENts with Atrial fibrillation) looked 
at stable patients with LVEF less than 40% and NYHA 
2-3 symptoms. It showed a reduced risk of  all-cause 
mortality and/or hospitalisation due to cardiovascular 
events[54]. However, ANtiarrhythmic trial with drone-
darone in Moderate-to-severe congestive heart failure 
Evaluating morbidity DecreAse (ANDROMEDA) trial 
(which looked at patients with severe HF in sinus rhythm 
and not AF) had to be terminated prematurely because 
dronedarone increased mortality in such patients[55]. As a 
result, it is no longer licensed for use in patients with un-
stable/severe HF. 
Rate vs  rhythm control: There is no convincing scien-
tific evidence so far to support a rhythm control strategy 
in preference to rate control. Given the negative impact 
of  AF in HF, the concept of  maintaining sinus rhythm 
appears attractive, yet a number of  randomised trials have 
failed to demonstrate improved long-term outcomes with 
a rhythm control approach[56-59]. The results are, however, 
limited by the fact that these trials were not exclusive to 
HF (for instance only 25% of  the AFFIRM cohort had 
depressed LV function) and it may be difficult to apply 
these findings to the HF population. On the other hand, 
there have been trials looking exclusively at HF patients 
as well. AF-CHF enrolled 1376 patients with systolic HF. 
They were randomized to either rhythm or rate control 
and followed up for 3 years looking at prospective data 
for mortality, HF admissions and stroke[52]. The differ-
ence in cardiovascular mortality observed in the two arms 
was not significant (27% in rhythm control vs 25% in rate 
control respectively). It is noteworthy, however, that only 
80% of  patients in the rhythm control arm remained 
entirely AF-free (65% when looking at overall 3 year fol-
low up visits as well as the 21% who crossed over to rate 
control arm)[11]. Interestingly, a post hoc analysis of  the 
AFFIRM trial looked at the rhythm control arm of  the 
trial. Sinus rhythm was associated with less severe NYHA 
symptomatic class and better functional capacity (assessed 
by 6-min walk test)[60]. Similarly, in a subgroup analysis of  
CHF-STAT trial, Kaplan-Meier analysis of  the survival 
curves for those who converted to SR with amiodarone 
showed significantly better survival as compared to those 
who remained in AF[51]. Same conclusion can be derived 
from the DIAMOND sub-study as well[53]. However, 
these results are based on post-hoc subgroup analyses 
and should be applied with caution. A recent meta-analy-
sis of  the 4 main randomised control trials of  AF rate vs. 
rhythm control in HF (incorporating 2486 patients) has 
demonstrated no significant difference in terms of  mor-
tality and thromboembolic events[61].
Thromboprophylaxis: Although beyond the scope of  
this review, it would be amiss not to mention the enor-
mous clinical, social and economic impact of  stroke in 
HF patients with AF. Due to various co-morbidities, 
patients with HF have a significantly higher risk of  
thromboembolic events particularly stroke. Hence, oral 
anticoagulation is imperative unless there are equally 
binding contraindications. ACCF/AHA/HRS guidelines 
have kept the option of  either aspirin or anticoagulation 
for patients with a CHADS2 score of  1 while European 
Society of  Cardiology (ESC) and Canadaian Cardiovascu-
lar Society (CCS) guidelines indicate anticoagulation for 
such patients in preference to aspirin. Nevertheless, there 
is unanimous agreement in recommending long-term 
anticoagulation for all patients with a CHADS2 score of  
2 and above[62]. Warfarin is well recognized in this regard 
and has been the mainstay of  thromboprophylaxis in 
AF[63] for the last 60 years. It has been shown to reduce 
the risk of  stroke by as much as 65% and is thrice as effi-
cacious as aspirin[64]. Its clinical utility, however, is fraught 
with a variety of  limitations (both real and perceived, by 
patients and physicians alike). These include a narrow 
therapeutic window, need for meticulous monitoring of  
INR levels, unreliable blood levels due to interaction with 
various drugs/food and risk of  bleeding in an increas-
ingly frail/ ageing population.
The last few years have witnessed the exciting devel-
opment of  a novel group of  oral anticoagulants (NO-
ACs) with the advantage of  rapid onset of  action, fewer 
drug/food interactions and predictable blood levels thus 
exonerating patients from laborious INR monitoring. 
They have been shown to carry a lesser risk of  intracra-
nial bleeding in comparison to warfarin while maintaining 
the same level of  protection against stroke. However, 
widespread use is restricted by higher costs, unavailabil-
ity of  a reversal agent in the event of  a major bleed and 
no validated lab markers of  anticoagulant effect[65]. The 
two main classes consist of  direct thrombin inhibitors 
(dabigatran) and activated factor X inhibitors (apixaban, 
rivaroxaban, edoxaban) while several others are under 
development. Dabigatran was the first to be approved by 
Food and Drug Administration in 2010 for non-valvular 
AF following the Randomized Evaluation of  Long-term 
anticoagulation therapY (RE-LY) trial[66] which enrolled 
18113 patients with AF. One-third of  the study popula-
tion had symptomatic HF or LVEF < 40%. Patients were 
randomized to receive either 150 or 110 mg twice daily 
(blinded dose groups) of  dabigatran or INR-guided war-
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farin therapy. In comparison to warfarin, 110 mg twice 
daily dose was non-inferior in efficacy and superior in 
safety while the 150 mg twice daily dose was superior in 
efficacy and had similar rates of  major bleeding. Conse-
quently, dabigatran has been recommended as an alterna-
tive to warfarin in recent ESC, AHA/ACCF as well as 
CCS guidelines[67-69]. Similarly, Rivaroxaban was studied in 
the Rivaroxaban Once daily oral direct factor Xa inhibi-
tion Compared with vitamin K antagonism for preven-
tion of  stroke and Embolism Trial in Atrial Fibrillation 
(ROCKET-AF) looking at over 14000 patients. Data 
demonstrate non-inferiority to warfarin in terms of  effi-
cacy. It was associated with less intracranial haemorrhage 
as well albeit a higher risk of  gastrointestinal bleed[70]. 
Finally, Apixaban is the only one so far which has been 
shown to be superior to warfarin in reducing the primary 
end-point of  thromboembolic events including stroke 
(annual event rate 1.27% vs 1.60%; P < 0.001 for nonin-
feriority; P = 0.01 for superiority). This is derived from 
the Apixaban in Preventing Stroke and Systemic Embo-
lism in Subjects With Nonvalvular Atrial Fibrillation trial 
which enrolled over 18000 patients. The 21% reduction 
in primary safety end-point was mainly derived from a 
lower likelihood of  haemorrhagic strokes. There was no 
significant difference in the rates of  ischaemic strokes be-
tween the two[71]. All three NOACs available so far have 
been licensed for use in non-valvular AF.
Non-pharmacological therapy
Drug therapy is the mainstay of  AF management. How-
ever, many patients are unable to achieve rhythm or 
rate control targets due to therapeutic inefficacy or side 
effects respectively. Consequently, device therapy and 
electrophysiological catheter interventions have gained 
importance. 
“Pace and ablate’’ strategy: Atrio-ventricular node 
(AVN) ablation accompanied by a permanent pacemaker 
is often used as an extreme option for definitive rate 
control. However, AF is not eliminated per se and rate 
control with a regular RR length may not suffice in com-
pensating for the haemodynamic detriment caused by A-V 
dys-synchrony and loss of  atrial systole. Thus, arguably, 
the procedure may only be of  symptomatic benefit[72]. 
Moreover, there is a potential for progressive inter-ven-
tricular dys-synchrony due to chronic RV pacing. Hence, 
cardiac resynchronisation therapy (CRT) has emerged as 
the pacing option of  choice in all patients with systolic 
HF[73,74] who require pacing for AVN ablation. On the 
other hand, it is well recognized that clinical response to 
CRT is hampered if  adequate AF rate control cannot be 
achieved. This is likely to be due to a lower percentage of  
biventricular pacing and here AVN ablation can be very 
helpful. This has been demonstrated in a recent meta-
analysis of  23 observational studies involving 7495 CRT 
patients (25% of  the total had AF). When compared to 
patients in sinus rhythm, presence of  AF conferred a 
higher likelihood of  CRT non-response and increased 
all-cause mortality (10.8% vs 7.1% per year, pooled RR = 
1.50, 95%CI: 1.08-2.09, P = 0.015). In addition, there was 
a lesser improvement in quality of  life, exercise capacity 
and LV end-systolic dimensions. On the other hand, in 
patients with AF, AVN ablation not only improved re-
sponse to CRT (RR = 0.40, 95%CI: 0.28-0.58, P < 0.001) 
but was associated with a reduced risk of  mortality as 
well[75]. A number of  other small, mostly single-centre, 
non-randomized studies of  CRT (in HF patients with 
AF) have also shown improvement in soft end-points 
such as reduced mitral regurgitation, improved LV ejec-
tion fraction and better exercise capacity but clearly more 
data is required[76-78]. For instance, a registry-based analysis 
of  patients with severe HF compared 139 patients who 
had AF with 445 in sinus rhythm. One year follow up re-
vealed comparable CRT-related improvement in NYHA 
symptom class and LV ejection fractions in the two co-
horts. Of  note, mortality was higher in the AF group (12% 
vs 7%; OR = 1.80, 95%CI: 0.95-3.4)[78]. Although the 
results are encouraging, yet large scale placebo controlled 
randomised trials are still required to confirm long term 
prognostic benefit.
AF ablation: As noted above, “pace and ablate” strategy 
is effective in controlling the ventricular rate but it does 
not eliminate AF as such. Also, like all invasive proce-
dures CRT is not free of  potential complications. Con-
sequently, radio-frequency catheter ablation (RFA) using 
pulmonary vein isolation (PVI) has gained momentum in 
the management of  AF. A number of  observational stud-
ies (albeit small) provide supportive data for such a strat-
egy. The non-randomized observational study by Hsu 
et al[79] compared 58 patients in HF with an equivalent 
number of  age/sex matched controls without HF. All 
underwent RFA for AF. At the completion of  one year, 
78% of  the HF cohort and 84% of  controls remained in 
sinus rhythm (although 50% had required a second pro-
cedure due to recurrence of  AF). RFA led to significantly 
improved LV function (mean increase 21%) in the HF 
cohort. In addition, significant improvement was seen in 
NYHA symptom class, quality of  life (assessed by SF-36 
QoL scores) and exercise capacity (assessed by bicycle-
ergometer stress test) as well. The trial was, however, not 
powered to look at mortality trends. Similar results have 
been obtained in a number of  other small non-random-
ized studies demonstrating improvement in LVEF and 
patient symptoms[80-82]. Pulmonary vein Antrum isola-
tion vs atrioventricular node ablation with Biventricular 
pacing for treatment of  atrial fibrillation in patients with 
congestive heart failure (PABA-CHF) was a multi-centre 
study which prospectively randomized 81 drug-refractory 
AF patients (with a LVEF of  40% or less and NYHA 
functional class 2-3) to undergo PVI or AVN ablation 
with biventricular ICD implant. They were followed up 
at 6 mo. The composite primary end point consisted 
of  LVEF, 6-min walk distance and Minnesota Living 
with Heart Failure score. PVI patients fared better in all 
three components of  the end point than the cohort who 
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underwent AVN ablation and biventricular pacing[83]. Re-
cently, MacDonald et al[84] conducted a randomised con-
trolled trial in HF patients comparing rhythm control by 
RFA (n = 22) to rate control by medical therapy (n = 19). 
RFA failed to show any significant improvement in ra-
dionuclide LV ejection fractions as compared to the rate 
control arm. Only 50% were able to retain sinus rhythm 
at the end of  one year and a significant (15%) complica-
tion rate was observed. A meta-analysis of  AF ablation 
trials in patients with moderate LV systolic dysfunction 
looked at 9 studies involving a total of  354 patients. RFA 
led to an overall improvement in LV systolic function. 
However, the results are limited by heterogeneous study 
cohorts and lack of  long-term outcome data[85]. Hence, 
large scale, multicentre, randomized controlled trials with 
longer follow up will be required for further definitive 
clarification. Finally, in patients undergoing cardiac sur-
gery, surgical ablation techniques (variations of  Cox Maze 
procedure) are available as a safe and effective alterna-
tive[86] including for those with depressed LV function[87].
FUTURE TRENDS
Selective AV nodal stimulation 
Selective AV nodal vagal stimulation (AVN-VS) has 
emerged as a potentially viable therapeutic intervention 
for ventricular rate control in AF. Loss of  vagal tone fol-
lowed by sympathetic overstimulation is thought to con-
tribute to the pathophysiology of  HF. Epicardial AV nod-
al fat pad stimulation (using catheter electrodes) targets 
parasympathetic efferents in the vagal ganglia and confers 
negative chronotropic and dromotropic effects. This can 
then be potentially used to modulate AF rate control 
in patients with HF. Small-scale, randomised preclinical 
case-control studies have shown effective heart rate con-
trol along with improvement in LV function in acute[88] as 
well as chronic settings[89]. Investigators induced HF and 
AF in canine models using rapid ventricular pacing for 4 
wk followed by continued rapid atrial pacing respectively. 
Similar reversible negative chronotropic effects have been 
demonstrated in a cohort of  25 patients who underwent 
efferent vagal nerve stimulation with a multipolar cath-
eter in superior vena cava or coronary sinus[90]. Although 
it is only hypothesis generating at this stage, yet it showed 
consistent slowing of  the heart rate and this was associ-
ated with improved LV function. Larger trials are needed 
to ascertain the true potential of  this technique.
Atrial-specific anti-arrhythmic agents 
Currently available anti-arrhythmic agents used for AF 
act on multiple ion-channels located in the atria as well 
as ventricles. Consequently, there is a risk of  ventricular 
pro-arrhythmia and this is a particular concern in pa-
tients with structural heart disease/HF. Development 
of  atrial specific anti-arrhythmics with a reduced risk 
of  ventricular pro-arrhythmia is indeed an attractive 
strategy[91]. Vernakalant is a potassium-channel blocker 
which has undergone successful phase Ⅱ and Ⅲ trials. 
It is different to the conventional class Ⅲ agents in that 
it selectively delays atrial repolarization by blocking atrial 
specific potassium-channels. As a result it suppresses AF 
by prolonging the atrial refractory period and is not as-
sociated with ventricular pro-arrhythmic effects such as 
QT prolongation and torsades[92]. A phase Ⅲ superiority 
study of  Vernakalant vs Amiodarone in Subjects With 
Recent Onset Atrial Fibrillation (AVRO) demonstrated 
superior efficacy of  vernakalant as compared to amioda-
rone[93]. However, only 20% of  the patients in the cohort 
had HF. Also, there is no experience yet in advanced HF 
as patients with unstable congestive HF, NYHA class 
4 symptoms, or HF requiring inotropes were excluded 
from the study.
Left atrial appendage occlusion devices
A significant minority of  patients in AF are unable to bene-
fit from oral anticoagulation-either due to contraindications 
(bleeding, allergy) or therapeutic failure (ischaemic stroke 
despite effective anticoagulation). Studies have shown that 
in non-rheumatic AF, left atrial appendage serves as the 
source of  thromboemboli in around 90% of  cases[94]. Con-
sequently, percutaneous devices for the occlusion/exclusion 
of  the left atrial appendage have emerged as a potentially 
promising answer to this challenging conundrum[95]. Results 
from the recent randomised WATCHMAN left atrial ap-
pendage system for embolic PROTECTion in patients with 
Atrial Fibrillation (PROTECT AF) trial have established 
the feasibility of  this technique[96] while demonstrating non-
inferiority with warfarin therapy. The initially high rate of  
procedural complications has subsequently improved with 
greater operator experience[97] and combination with PVI 
has been successfully carried out[98] as well. Long term 
outcome data is not available yet. Trials are also underway 
assessing further devices such as the Amplatzer cardiac plug 
and LARIAT suture delivery system[99].
Genomics 
Despite the frequent coexistence of  AF and HF, it is in-
triguing that more than half  of  even severe HF patients 
do not develop AF. It is postulated that there may be a 
genetic predilection for AF in certain HF patients. If  
such is the case, then modulating these factors may pro-
vide a potential therapeutic target. Indeed, familial clus-
tering of  AF is well recognized. Moreover, genome wide 
association studies have demonstrated several common 
AF-related mutations and polymorphisms[100]. Recently, a 
large population study showed a strong genetic associa-
tion between AF and a polymorphism in the ZFHX3 
gene (which encodes a cardiac transcription factor). 
This was associated with increased AF risk in HF pa-
tients when compared to the general population[101]. The 
mechanism by which this translates into pathology is not 
known. Polymorphisms have also been identified in the 
beta1-adrenergic receptor gene in patients with systolic 
HF and AF[102]. Again the exact significance is not clear 
yet but it may help risk stratify HF patients in terms of  
favourable response to beta blocker therapy[103].
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Upstream therapy 
Apart from ion-channel blockers, other pharmacologic 
agents have been investigated for potential anti-AF ef-
fects with the hope that modification of  the arrhythmo-
genic atrial substrate and neuroendocrine axis may be 
of  benefit. Limited data is available for polyunsaturated 
fatty acids[104], statin therapy[105] and renin-angiotensin-
aldosterone system blockade[106,107]. At best, the findings 
have been inconclusive so far and larger randomized con-
trolled trials are required[108]. 
CONCLUSION
HF and AF have emerged as global cardiovascular 
epidemics. They commonly coexist accounting for an 
enormous clinical and economic burden on healthcare. 
Emerging evidence suggests that AF confers an adverse 
prognostic impact on HF. Despite the negative impact 
of  AF in HF, to date there is no definite evidence that 
rhythm control is prognostically superior to a rate con-
trol strategy. Trials of  AF ablation have been encourag-
ing yet larger studies (looking at hard end-points) are 
required before it can be incorporated into mainstream 
clinical practice. Development of  novel anticoagulants 
constitutes an important step towards minimizing the 
thromboembolic toll of  AF. Genomics, pharmacological 
“upstream” modification of  the atrial substrate and de-
velopment of  selective atrial anti-arrhythmic agents pro-
vide further insights into this exciting field. It is not clear 
yet whether these will translate into clinically tangible 
benefits for the HF patient. 
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